SCHEMBL344484

SCHEMBL344484

CC(C)(C)OC(=O)N1CCC(C(C(=O)O)C(=O)O)C1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.47
GPR119 Q8TDV5 3/20 0.46
RECQL P46063 1/20 0.44
EPHX1 P07099 1/20 0.44
MMP13 P45452 4/20 0.44
DPP4 P27487 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
USP30 Q70CQ3 1/20 0.43
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MMP1 P03956 2/20 0.42
MMP3 P08254 2/20 0.42
MMP7 P09237 2/20 0.42
MMP9 P14780 2/20 0.42
MMP8 P22894 2/20 0.42
MMP2 P08253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19510778 1.00 HPGD (0.47) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL344483 1.00 HPGD (0.47) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL4612534 0.90 HPGD (0.53) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL19510734 0.89 GPR119 (0.44) HPGDGPR119RECQLMMP13DPP4
SCHEMBL27204263 0.86 GPR119 (0.48) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL27157592 0.86 GPR119 (0.48) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL13300114 0.86 GPR119 (0.48) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL4455379 0.85 DPP4 (0.47) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL21645191 0.85 GPR119 (0.45) HPGDGPR119RECQLEPHX1MMP13
SCHEMBL4546635 0.84 HPGD (0.49) HPGDGPR119RECQLEPHX1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246936-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE OYSTER POINT PHARMA INC (US) 2024-07-25 US claimed
US-20230295126-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE TARGACEPT, INC. 2023-09-21 US claimed
US-20160046609-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE CATALYST BIOSCIENCES, INC. 2016-02-18 US claimed
EP-2358670-B1 A process for the preparation of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate and intermediates therefor TARGACEPT INC (US) 2012-10-24 EP claimed
US-8153821-B2 Compounds TARGACEPT, INC. (US) 2012-04-10 US claimed
US-20120015983-A1 Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine TARGACEPT, INC. (US) 2012-01-19 US claimed
US-20110281895-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE TARGACEPT, INC. (US) 2011-11-17 US claimed
US-20110269975-A1 NOVEL COMPOUNDS TARGACEPT, INC. (US) 2011-11-03 US claimed
EP-2358670-A2 Novel compounds Targacept Inc. (US) 2011-08-24 EP claimed
EP-2358705-A1 (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS Targacept Inc. (US) 2011-08-24 EP claimed
WO-2010065449-A1 (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS TARGACEPT, INC. (US) 2010-06-10 WO claimed
WO-2010065447-A2 NOVEL COMPOUNDS TARGACEPT, INC. (US) 2010-06-10 WO claimed
WO-2024217537-A1 TERTIARY AMINE COMPOUND AS WELL AS PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2024-10-24 WO disclosed
US-20240246936-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE OYSTER POINT PHARMA INC (US) 2024-07-25 US disclosed
US-20230295126-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE TARGACEPT, INC. 2023-09-21 US disclosed
CN-107567443-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-28 CN disclosed
WO-2010065449-A1 (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS TARGACEPT, INC. (US) 2010-06-10 WO disclosed
WO-2010065443-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE TARGACEPT, INC. (US) 2010-06-10 WO disclosed
WO-2010065447-A2 NOVEL COMPOUNDS TARGACEPT, INC. (US) 2010-06-10 WO disclosed
WO-2010065447-A2 NOVEL COMPOUNDS TARGACEPT, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015983-A1 Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, REN, SRMS HPGD 1606/4885GPR119 3250/4885RECQL 2856/4885
US-20240246936-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE DPYD, NUDT5, DHPS HPGD 661/4885GPR119 4298/4885RECQL 991/4885
US-20110269975-A1 NOVEL COMPOUNDS CHRNB2, CHRNA2, CHRNA5 HPGD 2489/4885GPR119 87/4885RECQL 3461/4885
US-20160046609-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE DPYD, DHPS, NUDT5 HPGD 735/4885GPR119 4289/4885RECQL 1304/4885
US-20230295126-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE DPYD, DHPS, NUDT5 HPGD 739/4885GPR119 4309/4885RECQL 1157/4885
US-20110281895-A1 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE DPYD, DHPS, NUDT5 HPGD 841/4885GPR119 4193/4885RECQL 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.